In the treatment of common malignant tumors, surgery is the first choice. Generally, surgery is the main treatment for solid tumors in the early and middle stages, with corresponding adjuvant chemotherapy and radiotherapy for pathology and disease development, followed by maintenance treatment mostly with herbal medicine. With the development of technology, some conventional adjuvant therapies have been selectively replaced by some new therapies. Molecular targeted drugs: Targeted drugs are increasingly used. Since 2000, more than ten kinds of targeted drugs have been produced at home and abroad, which have specific effects on tumor-related molecular targets and selective killing effects on tumor cells, with less toxic side effects than conventional chemotherapy drugs, and can be effective for some cancers that are not sensitive to radiotherapy. The common targeted drugs include ERSA and Troche for lung cancer; Herceptin for breast cancer; Siroda for gastric cancer; Merova for malignant lymphoma; Epiduo for intestinal cancer; Gleevec for mesenchymal tumor; and Avastin and Endo for tumor vascular inhibition, etc. Molecular targeted drugs also have disadvantages and are not suitable for every cancer patient. Although the side effects of targeted drugs are less compared to normal chemotherapy, they still have great reactions in some patients; more than half of the patients using targeted drugs will develop drug resistance within a certain period of time. Biologic therapy: Biologic therapy is very broad, there are gene therapy, cell therapy, immunotherapy and so on. DC cells, or dendritic cells, are the most powerful and only specialized antigen-presenting cells known to activate T cells in vivo, and are central to the initiation, regulation and maintenance of the immune response. DC cells loaded with tumor antigens are cultured through massive in vitro activation and transfused back to patients when the number of cells reaches a certain number, which can induce a strong anti-tumor immune response in the body. CIK cells are cytokine-induced killer cells, a new type of immunologically active cells with strong proliferative capacity, strong cytotoxic effect and certain immunological properties. co-culture of DC cells and induced CIK cells improves the proliferation rate and killing activity of the cells, and makes their killing effect on tumor cells more specific. Moreover, DC-CIK cells can kill tumor cells in blood, gastrointestinal, respiratory, urinary and reproductive systems, etc. They can precisely kill tumor cells during the treatment process without any harm to patients. DC-CIK cells can remove the tiny tumor cells hidden in the human body by mobilizing the immune function of the body during the treatment process; meanwhile, cellular immunotherapy will stimulate the anti-tumor active immune cells in the human body to induce the patient’s own immune system to produce specific and long-term lasting immune response to cancer cells, thus effectively preventing the occurrence and development of malignant tumors. In the actual treatment plan of malignant tumor, we generally choose the conventional treatment and adjuvant treatment according to the patient’s specific condition, the patient’s physical condition, the development of the disease, the degree of malignancy, the patient’s tolerance range, etc. Especially for advanced stage patients, there is no best tumor treatment plan, only the most suitable treatment plan for the patient. However, with the development of technology, cell therapy is the most powerful means to overcome malignant tumors in the future.